natgillin/translations-raw huggingface dataset:
Der er rapporteret bivirkninger hos 5- 14% af de patienter, som får ciprofloxacin.
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin.
De hyppigste bivirkninger involverer mave- tarmkanalen og centralnervesystemet.
Most frequent adverse effects involve the gastro-intestinal tract and the central nervous system.
Følgende bivirkninger er blevet observeret:
The following undesirable reactions have been observed:
Meget almindelig (≥ 1/ 10) Almindelig (≥ 1/ 100 til, < 1/ 10) Ikke almindelig (≥ 1/ 1 000 til, < 1/ 100)
Very common (≥ 1/ 10) Common (≥ 1/ 100 to < 1/ 10) Uncommon (≥ 1/ 1 000 to < 1/ 100) Rare (≥ 1/ 10,000 to < 1/ 1,000) Very rare (< 1/ 10,000), not known (cannot be estimated from the available data)
Ikke almindelig: moniliasis
Uncommon: moniliasis
Sjælden: leukopeni (granulocytopeni), anæmi, leukocytosis, ændrede protrombinværdier, trombocytopeni, trombocytæmi (thrombocytose).
Rare: leukopenia (granulocytopenia), anaemia, leukocytosis, thrombocytopenia, thrombocytemia (thrombocytosis).
Immunsystemet:
prothrombin
Sjælden: ødem (perifert, angio -, facialt), allergisk reaktion, lægemiddelfeber, anafylaktoid (anafylaktisk) reaktion.
Rare: oedema (peripheral, angio, facial), allergic reaction, drug fever, anaphylactoid (anaphylactic) reaction.
Sjælden: hyperglykæmi.
Rare: hyperglycaemia.
Meget sjælden: parosmi (nedsat lugtesans), anosmi (forsvinder normalt efter afbrydelse), grand mal - anfald, unormal (ustabil) gang, intrakraniel hypertension, ataksi, hyperæstesi, hypertoni.
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension, ataxia, hyperesthesia, hypertonia.
Sjælden: synsforstyrrelser, diplopi, chromatopsi.
Rare: disturbed vision, diplopia, chromatopsia.
Øre og labyrint:
12 Ear and labyrinth disorders:
Sjælden: tinnitus, forbigående høretab (især høje frekvenser).
Rare: tinnitus, transient hearing loss (particularly high frequencies).
I meget sjælde tilfælde er ventrikulære arytmier, forlænget QT- interval og torsades de pointes blevet rapporteret.
In very rare cases ventricular arrhythmia, QT interval prolongation and torsades de pointes have been reported.
(thrombo) flebitis.
(thrombo) phlebitis.
Sjælden: dyspnø, laryngealt ødem.
Rare: dyspnoea, laryngeal oedema.
13 Meget sjælden: moniliasis (gastro- intestinal), pankreatitis.
Very rare: moniliasis (gastro-intestinal), pancreatitis.
Ikke almindelig: pruritis, papillo- makulært udslæt, urticaria.
Uncommon: pruritis, papillo-macular rash, urticaria.
Meget sjælden: erythema nodosum, erythema multiforme (mindre), Stevens- Johnson syndrom, epidermal nekrolyse (Lyell Syndrom), petechia.
Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome), petechia.
Meget sjælden: forøgelse af amylase/ lipaseniveauer.
13 Very rare: increment of amylase/ lipase levels.
4. 4).
Very rare: asthenia, a transient impairment of kidney function to transient renal failure, photosensitivity (see Section 4.4).
Ved hæmodialyse eller peritoneal dialyse elimineres kun en beskeden mængde ciprofloxacin (mindre end 10%).
At haemodialysis or peritoneal dialysis only a modest amount of ciprofloxacin (less than 10%) is eliminated.
Antibakterielle quinoloner, ATC- kode:
Antibacterial quinolones, ATC code:
Virkning:
Mode of action:
14 Ciprofloxacin har en hurtig bakteriedræbende virkning, både i vækstfasen og i hvilefasen.
Ciprofloxacin has a rapid bactericidal effect, both in the growth phase and in the rest phase.
Enzymet DNA- gyrase spiller en essentiel rolle i denne proces.
The enzyme DNA-gyrase plays a crucial role in this process.
Ciprofloxacin hæmmer DNA- gyrase, hvilket resulterer i inhibition af DNA- syntese.
Ciprofloxacin inhibits DNA-gyrase, resulting in inhibition of DNA synthesis.
Ciprofloxacin er effektivt in vitro mod en lang række Gram- negative aerobe bakterier, inklusiv P. aeruginosa.
Ciprofloxacin is effective in vitro against a large number of Gram-negative aerobic bacteria including P. aeruginosa.
Det er også effektivt mod Gram- positive organismer, som f. eks. staphylokokker og streptokokker.
It is also effective against Gram-positive organisms, such as staphylococci and streptococci.
Resistens mod ciprofloxacin udvikles i stadier gennem genome mutationer (multiple- trin typen).
Resistance to ciprofloxacin develops in stages through genomic mutations (multiple-step type).
Overførbar plasmid- medieret quinolonresistens associeret med qnr er blevet påvist i quinolon - resistente kliniske stammer af E. coli og Klebsiella spp.
Transferable plasmid-mediated quinolone resistance associated with qnr has been detected in quinolone-resistant clinical strains of E. coli and Klebsiella spp.
Som et resultat af denne handlingsmekanisme udviser ciprofloxacin ikke krydsresistens med andre vigtige, kemisk forskellige grupper af stoffer, som f. eks. beta- laktam antibiotika, aminoglycosider, tetracycliner, makrolider og polypeptider, sulfonamider, trimethoprim og nitrofurantoin.
As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine.
Udvikling af resistens mod ciprofloxacin og andre fluorquinoloner er blevet observeret ved staphylokokker, især methicillin - resistent S. aureus, P. aeruginosa, E. coli og E. faecalis (se følsomhedstabellen).
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillin- resistant S. aureus, P. aeruginosa, E. coli and E. faecalis (see the sensitivity table).
Særligt patienter, der gennemgår langtidsbehandling (f. eks. ved cystisk fibrose, osteomyelitis), eller patienter, som er ekstremt modtagelige for infektioner (f. eks. ved selektiv profylakse hos visse grupper af neutropene patienter, kunstig vejtrækning) viser den højeste risiko.
Especially patients undergoing long-term treatment (e. g. in cystic fibrosis, osteomyelitis), or patients who are extremely susceptible to infections (e. g. in selective prophylaxis in certain groups of neutropenic patients, artificial ventilation) show the highest risk.
Det anbefales derfor at undersøge resistens- forhold regelmæssigt.
Regular determination of resistance is therefore recommended.
- Enterobacteriaceae: ≤ 0, 5 µg/ ml for følsomme, > 1 µg/ ml for resistente;
- Enterobacteriaceae: ≤ 0.5 µg/ ml for susceptible, > 1 µg/ ml for resistant;
- Pseudomonas spp. ≤ 0, 5 µg/ ml for følsomme, > 1 µg/ ml for resistente;
- Pseudomonas spp. ≤ 0.5 µg/ ml for susceptible, > 1 µg/ ml for resistant;
- Acinetobacter spp. ≤ 1 µg/ ml for følsomme, > 1 µg/ ml for resistente;
- Acinetobacter spp. ≤ 1 µg/ ml for susceptible, > 1 µg/ ml for resistant;
- S. pneumonia ≤ 0, 125 µg/ ml for følsomme, > 2 µg/ ml for resistente;
- S. pneumonia ≤ 0.125 µg/ ml for susceptible, > 2 µg/ ml for resistant;
- Staphylococcus spp. ≤ 1 µg/ ml for følsomme, > 1 µg/ ml for resistente;
- Staphylococcus spp. ≤ 1 µg/ ml for susceptible, > 1 µg/ ml for resistant;
- H. influenza og M. catarrhalis ≤ 0, 5 µg/ ml for følsomme, > 0, 5 µg/ ml for resistente.
- H. influenza and M. catarrhalis ≤ 0.5 µg/ ml for susceptible, > 0.5 µg/ ml for resistant.
Break points ikke relateret til arter er ≤ 0, 5 µg/ ml for følsomme og > 1 µg/ ml for resistente organismer.
Non-species related breakpoints are ≤ 0,5 µg/ ml for susceptible, and > 1 µg/ ml for resistant organisms.
Almindeligt følsomme arter Gram- negative aerobe arter Citrobacter spp.
Commonly susceptible species Gram-negative aerobe species Citrobacter spp.
Proteus mirabilis Proteus vulgaris Serratia liquefaciens Serratia marcescens
Proteus mirabilis Proteus vulgaris Serratia liquefaciens Serratia marcescens Species for which acquired resistance may be a problem Gram-positive aerobes Coagulase-negative Staphylococcus Enterococcous faecalis MRSA* Staphylococcus aureus Staphylococcus aureus (methicillin susceptible) Streptococcus spp.
Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae PEN- R Streptococcus pyogenes Gram- negative aerober Acinetobacter spp.
Streptoococus agalactiae Streptococcus pneumoniae S. pneumoniae PEN-R Streptococcus pyogenes Gram-negative aerobes Acinetobacter spp.
Amp- C producerende Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca Pseudomonas aeruginosa Inherente resistente organismer Gram- positive aerober Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gram- negative aerober E. coli multi- resistent Providencia spp.
Amp-C producing Escherichia coli Klebsiella pneumoniae Klebsiella oxytoca Pseudomonas aeruginosa Inherently resistant organisms Gram-positive aerobes Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gram-negative aerobes
Extended Spectrum Beta- lactamases MRSA:
Extended Spectrum Beta-lactamases MRSA:
Methicillin- resistent Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus
Maksimal plasmakoncentration nås 0, 5 - 2 timer efter indtagelse af 50 - 1000 mg p. o. og varierer fra 0, 3 - 5, 9 mg/ l.
The peak plasma concentration is reached 0.5 - 2 hours after taking 50 - 1000 mg p. o. and varies from 0.3 - 5.9 mg/ l.
Biotilgængeligheden for ciprofloxacin efter oral administration er mellem 70% og 85%.
The bioavailability of ciprofloxacin after oral administration is between 70% and 85%.
Biotilgængeligheden er lavere, hvis antacider, som indeholder aluminium og/ eller magnesiumhydroxid og calcium og jernsalte, anvendes konkomitant.
The bioavailability is lower if antacids that contain aluminium and/ or magnesium hydroxide, and calcium and iron salts are used concomitantly.
0, 1 µg/ ml).
Twelve hours after i. v. administration of 200 mg the plasma concentration is still higher than the MIC values of the majority of clinically relevant pathogens (approximately 0.1 µg/ ml).
I steady- state- forhold er ciprofloxacins tilsyneladende fordelingsvolume mellem 1, 7 og 2, 7 l/ kg.
In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/ kg.
Dette relativt høje fordelingsvolumen indikerer en effektiv vævs - og væskepenetration.
This relatively high distribution volume indicates an effective tissue and fluid penetration.
16 Koncentrationerne i lungevæv, gynækologisk væv og prostatavæv og væske var også signifikant højere end serumkoncentrationen.
Concentrations in pulmonary tissue, gynaecological tissue and prostate tissue and fluid were also significantly higher than the serum concentration.
Koncentrationen af ciprofloxacin i sputum består af 50- 70% af serumkoncentrationen.
The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration.
Ciprofloxacins plasmaprotein- binding ligger mellem 16% og 28% og er ikke afhængig af koncentrationen og pH (bestemmes ved hjælp af ultrafiltration).
The plasma protein binding of ciprofloxacin is situated between 16% and 28% and is not dependent on the concentration and pH (determined by means of ultrafiltration).
En del af det omdannes til desethylen -, sulfo -, oxo - og formylciprofloxacin.
Part of it is converted into desethylene-, sulpho-, oxo- and formylciprofloxacin.
Efter oral administration udskilles 70% ciprofloxacin uændret, og efter intravenøs administration ca.
70% and after i. v. administration for approx.
77%.
77%.
Efter oral administration udskilles 45% uændret i urinen og 25% i afføringen.
After oral administration 45% is excreted unchanged in the urine and 25% is excreted in the faeces.
Efter intravenøs administration udskilles 62% uændret i urinen og 15% i afføringen.
After i. v. administration 62% is excreted unchanged in the urine and 15% is excreted in the faeces.
Efter oral administration udskilles 19% og efter intravenøs administration udskilles 12% af ciprofloxacin i urinen og i afføringen i form af metabolitter.
After oral administration 19% and after i. v. administration 12% of ciprofloxacin is excreted in the urine and faeces in the form of metabolites.
Efter oral administration angiver et større antal metabolitter nogen grad af first- pass- metabolisme, hvilket hovedsageligt danner sulfociprofloxacin.
A larger number of metabolites after oral administration indicates some degree of first-pass metabolism, mainly forming sulphociprofloxacin.
3 gange højere end kreatininclearance.
The renal clearance constitutes 60%-70% of the total body clearance and is approximately 3 times higher than the creatinine clearance.
Eliminationshalveringstiden for ciprofloxacin efter enkelt eller multipel oral dosering er mellem 3, 4 og 6, 9 timer.
The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3.4 and 6.9 hours.
Efter enkelt og multipel intravenøs dosering er eliminationshalveringstiden mellem 3 og 4, 6 timer.
After single and multiple i. v. dosage the elimination half-life is between 3 – 4.6 hours.
Karakteristika hos patienter:
16 Characteristics in patients:
Hos patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/ min) kan eliminationshalveringstiden forlænges med en faktor på 2.
In patients with severely impaired renal function (creatinine clearance < 30 ml/ min) the elimination half-life may be prolonged by a factor of 2.
Oral administration af 20 mg/ kg to gange dagligt til børn med cystisk fibrose giver en eksponering, der kan sammenlignes med eksponeringen hos voksne efter en oral dosis på 750 mg to gange dagligt.
Oral administration of 20 mg/ kg twice daily to children with cystic fibrosis gives an exposure that is comparable to that in adults following an oral dose of 750 mg twice daily.
Som ved andre gyrase- inhibitorer kan ciprofloxacin fremkalde ledskader hos unge dyr i vækstfasen.
Like with other gyrase inhibitors, ciprofloxacin may induce joint damage during the growth phase of juvenile animals.
Ciprofloxacins fototoksiske, fotomutagene og fotocarcinogene potentiale kan sammenlignes med andre gyrase- inhibitorer.
The phototoxic, photomutagenic and photocarcinogenic potential of ciprofloxacin is comparable to that of other gyrase inhibitors.
Andre prækliniske virkninger sås kun ved eksponeringer, som på tilstrækkelig vis overstiger den maksimale eksponering hos mennesker, således at der på baggrund af dyredata kan ses bort fra bekymringer vedr. sikkerhed hos mennesker.
Other preclinical effects were observed only at exposures that were sufficiently in excess of the maximum human exposure so that concern for human safety is negligible.
17 Natriumchlorid Saltsyre (E 507) til justering af pH Vand til injektioner
Lactic acid (E 270) Sodium chloride Hydrochloric acid (E 507) for pH adjustment Water for injections
4.
Ciprofloxacin Hikma cannot be mixed with solutions that are not stable at a pH of approximately 4.
Klart hætteglas af type 1 med chlorbutylgummiprop og aluminum flip- off- hætte.
Type I, clear glass vial, fitted with a chlorobutyl rubber stopper and aluminium flip-off caps.
1, 5 10 eller 20 hætteglas.
1.5 10 or 20 vials.
Brug kun klare opløsninger og ubeskadigede beholdere.
17 Use only clear solutions and undamaged containers.
Ikke anvendte lægemidler samt affald heraf og hætteglas bør destrueres i henhold til lokale retningslinier.
Any unused solution and the vial should be adequately disposed of, in accordance with local requirements.
Skal bruges umidelbart efter åbning af hætteglasset.
To be used immediately after the vial is opened.
Ciprofloxacin Hikma er kompatibelt med fysiologisk natriumchloridopløsning, Ringers opløsning, Ringers laktat- opløsning, 50 mg/ ml (5%) eller 100 mg/ ml (10%) glukoseopløsning og 50 mg/ ml (5%) glukoseopløsning med 2, 25 mg/ ml (0, 225%) eller 4, 5 mg/ ml (0, 45%) natriumchloridopløsning og 10% fruktoseopløsning.
Ciprofloxacin Hikma is compatible with physiological sodium chloride solution, Ringer’ s solution, Ringer’ s lactate solution, 50 mg/ ml (5%) or 100 mg/ ml (10%) glucose solution and 50 mg/ ml (5%) glucose solution with 2.25 mg/ ml (0.225%) or 4.5 mg/ ml (0.45%) sodium chloride solution and 10% fructose solution.
Kompatibilitet med disse opløsninger er bevist i ciprofloxacin - koncentrationer på 1 mg/ ml.
Compatibility with these solutions has been proven in ciprofloxacin concentrations of 1 mg/ ml.
Kemisk og fysisk anvendelsesstabilitet er blevet påvist umiddelbart efter fortynding, efter 24 timer ved 2- 8 °C og efter 24 timer ved stuetemperatur.
Chemical and physical in-use stability has been demonstrated immediately after dilution, after 24 hours at 2-8°C and after 24 hours at room temperature.
Estrada do Rio da Mó n. º 8, 8A e 8B – Fervença 2705- 906 Terrugem SNT Portugal Tlf.: +351 219 608 410 Fax: +351 219 615 102 e- mail: geral@ hikma. pt
Estrada do Rio da Mó n. º 8, 8A e 8B – Fervença 2705-906 Terrugem SNT Portugal Tel.: +351 219 608 410 Fax: +351 219 615 102 e-mail: geral@hikma. pt
18 10.
.
19 ETIKETTERING
19 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Æske
Carton box
Ciprofloxacin Hikma 200 mg/ 100 ml, infusionsvæske, opløsning [Udfyldes nationalt] ciprofloxacin
Ciprofloxacin Hikma 200 mg/ 100 ml, solution for infusion [To be completed nationally] ciprofloxacin
Ciprofloxacin laktat, der svarer til 2 mg ciprofloxacin.
Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
Læs vedlagte indlægsseddel.
See enclosed leaflet.
Opbevares i den originale yderpakning indtil brug for at beskytte mod lys.
Keep the vial in the outer carton until time of use in order to protect from light.
Eventuel uanvendt opløsning og hætteglasset skal bortskaffes på en hensigtsmæssig måde i overensstemmelse med lokale retningslinier.
Any unused solution and the vial should be adequately disposed of in accordance with local requirements.
Estrada do Rio da Mó, 8, 8A e 8B - Fervença 2705- 906 Terrugem SNT Portugal Tlf.: +351 219 608 410 Fax: +351 219 615 102 geral@ hikma. pt
Estrada do Rio da Mó, 8, 8A e 8B - Fervença 2705-906 Terrugem SNT Portugal Tel.: +351 219 608 410 Fax: +351 219 615 102 geral@hikma. pt
Batch nr. {xxxxxx}
Batch nr. {xxxxxx}
Fritaget fra krav om blindeskrift.
Not applicable.
Ciprofloxacin Hikma 200 mg/ 100 ml, infusionsvæske, opløsning [Udfyldes nationalt] ciprofloxacin Intravenøs brug
Ciprofloxacin Hikma 200 mg/ 100 ml, solution for infusion [To be completed nationally] ciprofloxacin Intravenous use
Batch nr.
Batch nr.
{xxxxxx}
{xxxxxx}
Præsentation af 200 mg/ 100 ml:
Presentation of 200 mg/ 100 ml:
Lad derfor være med at give den til andre.
It may harm them, even if
Ciprofloxacin Hikmas virkning, og hvad du skal bruge det til 2.
What Ciprofloxacin Hikma is and what it is used for 2.
Det skal du vide, før du begynder at tage Ciprofloxacin Hikma 3.
Before you use Ciprofloxacin Hikma 3.
Sådan skal du bruge Ciprofloxacin Hikma 4.
How to use Ciprofloxacin Hikma 4.
Sådan opbevarer du Ciprofloxacin Hikma 6.
How to store Ciprofloxacin Hikma 6.
Ciprofloxacin Hikma bruges til behandling af alvorlige og/ eller livstruende infektioner forårsaget af ciprofloxacin- følsomme mikroorganismer.
Ciprofloxacin Hikma is used for the treatment of severe and/ or life-threatening infections caused by ciprofloxacin-sensitive microorganisms.
Følgende infektioner kan behandles intravenøst (gennem blodet) med Ciprofloxacin Hikma: • komplicerede urinvejsinfektioner • visse infektioner i de nedre luftveje, herunder lungebetændelse • komplicerede infektioner i huden og bløddelene • knogleinfektioner
The following infections may be treated intravenously (via the blood) with Ciprofloxacin Hikma: • complicated urinary tract infections • certain lower respiratory tract infections including pneumonia • complicated skin and soft tissue infections • bone infections.
Cystisk fibrose er en arvelig sygdom i visse kirtler.
Children and Adolescents Ciprofloxacin Hikma can also be used for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged 5-17 years with cystic fibrosis (also called mucoviscidosis), a hereditary disease of specific glands.
Sygdommen påvirker lungerne, svedkirtlerne og fordøjelsessystemet og giver kroniske åndedræts - og fordøjelsesproblemer.
It affects the lungs, sweat glands and the digestive system causing chronic respiratory and digestive problems.
DET SKAL DU VIDE, FØR DU BEGYNDER AT BRUGE CIPROFLAXACIN HIKMA
BEFORE YOU USE CIPROFLOXACIN HIKMA
Brug IKKE Ciprofloxacin Hikma: • hvis du er overfølsom (allergisk) over for ciprofloxacin eller et af de øvrige indholdsstoffer i Ciprofloxacin Hikma eller anden medicin af quinolontypen • til børn under 5 år • til børn og unge i voksealderen, bortset fra til behandling af akutte infektioner i de nedre luftveje forårsaget af Pseudomonas aeruginosa- bakterier hos børn og unge i alderen 5- 17 år med cystisk fibrose • hvis du har tidligere tendon- lidelse i forbindelse med indgivelse af fluorquinolone • hvis du er gravid eller ønsker at blive gravid • hvis du ammer • hvis Ciprofloxacin Hikma og tizanidin (bruges til at behandle muskelkramper) gives samtidigt.
Do NOT use Ciprofloxacin Hikma: • If you have known allergic reaction (hypersensitivity) to ciprofloxacin or any of the other ingredients of Ciprofloxacin Hikma or other medicines of the quinolone type • In children aged below 5 years • In children and growing adolescents except for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged 5-17 years with cystic fibrosis • In patients with a history of tendon disorder related to fluoroquinolone administration • If you are pregnant or wish to become pregnant • If you are breast-feeding. • If Ciprofloxacin Hikma and tizanidine (used to treat muscle spasms) are given at the same time.
25 Vær ekstra forsigtig med at bruge Ciprofloxacin Hikma Du bør underrette din læge, hvis en af nedennævnte forholdsregler eller advarsler er eller var gældende for dig.
24 Take special care with Ciprofloxacin Hikma You should consult your doctor if one of the precautions and warnings mentioned below are or were applicable to you in the past.
Inden behandling med Ciprofloxacin Hikma – hvis du har eller har haft en af følgende sygdomme: • konvulsioner (krampeanfald), epilepsi eller anden hjernesygdom, f. eks. nedsat blodomløb i hjernen, slagtilfælde eller øget følsomhed over for krampeanfald, da nogle af ciprofloxacins mulige bivirkninger kan skade hjernen. • livstruende øget hjertefrekvens (torsade de pointes).
Before starting treatment - if you suffer or have suffered from one of the following diseases: • convulsions (seizures), epilepsy or another brain disease, for example decreased blood circulation in the brain, stroke or increased sensitivity to convulsions, since possible side effects of ciprofloxacin may cause damage to the brain. • life-threatening increase heart rate (torsade de pointes).
Tal med din læge, hvis du har denne sygdom. • myastenia gravis (en særlig type muskelsvaghed).
If you suffer from this disease, you should consult your doctor. • myastenia gravis (a particular type of muscle weakness).
Du bør derfor tale med din læge, hvis der er tegn på forværring af myastenia gravis. • tidligere leversvigt.
In case of any symptom indicating an exacerbation of myastenia gravis, you should therefore consult your doctor. • liver impairment in the past.
Du skal straks tale med din læge, hvis der opstår symptomer, som f. eks. hvis huden eller det hvide i øjnene bliver gullig. • betydelig nyresvigt.
When symptoms occur, such as yellowing of the skin or whites of the eyes, you should immediately consult your doctor. • significant renal impairment.
Din læge vil omhyggeligt kontrollere din nyrefunktion. • glucose- 6- phosphat- dehydrogenase- defekt (arvelig sygdom i de røde blodlegemer på grundlag af en defekt i et enzym).
Your doctor will check your renal function carefully. • glucose-6-phosphate dehydrogenase defect (hereditary disease of the red blood cells based on a defect in an enzyme).
Under eller efter behandling – hvis nogle af følgende tilstande opstår: • en følelse af depression eller forvirring efter indgivelse af Ciprofloxacin Hikma.
During or after treatment - if one of the following conditions occurs: • feeling depressed or confused after administration of Ciprofloxacin Hikma.